A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

NCT01324388 · Completed

Last updated 2026-05-28

This study tests how the drug LY2189265 affects the levels of lisinopril in the blood of adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 51 people

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2011-03 · est. completion 2011-08

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT01324388 ↗

Description as written by the study sponsor.

The purpose of this study is twofold: 1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril. 2. To evaluate the effect of LY2189265 on heart rate and blood pressure in healthy volunteers when taken with a Beta-blocker drug (metoprolol). In Part 1, participants will receive four weekly injections of LY2189265 with continued use of normal lisinopril therapy. Part 2 is a cross-over study design. Participants will receive a single injection of LY2189265 in one period, and seven daily doses of metoprolol and a single injection of LY2189265 in another period.

Treatments tested

LY2189265 also known as dulaglutide Biologic

Administered subcutaneously
Metoprolol Drug

Administered orally
Lisinopril Drug

Administered orally
Placebo Drug

Administered subcutaneously

Main thing measured	Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01324388 ↗